Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AcNK-Sup003
- Development stage
- Phase 1
- Lead developer
- SupermAb
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**AcNK-Sup003** is an investigational, cryopreserved natural killer cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma. The product consists of non-genetically modified NK cells bearing covalently and directionally conjugated bispecific antibodies that recognize both CD19 and CD20 on malignant B cells. This antibody-cell conjugate approach is intended to direct NK-cell-mediated cytotoxicity toward CD19- and CD20-expressing B-cell lymphoma cells. It is being developed by SupermAb (Beijing) Biotech and evaluated in investigator-initiated early clinical studies at Huazhong University of Science and Technology.
- Other names
- AcNK-Sup003 cell injectionAcNK-Sup-003 cell injectionAcNK-Sup 003 cell injectionCD20/CD19 cell injection
02
Targets
Beyond the preview
Go deeper on AcNK-Sup003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AcNK-Sup003.